

Michael N Dworzak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6307568/publications.pdf>

Version: 2024-02-01

174
papers

9,434
citations

36303

51
h-index

42399

92
g-index

176
all docs

176
docs citations

176
times ranked

8788
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29341.	1.5	5
2	Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS. <i>Haematologica</i> , 2022, 107, 759-764.	3.5	3
3	UMAP Based Anomaly Detection for Minimal Residual Disease Quantification within Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 898.	3.7	8
4	Automated identification of cell populations in flow cytometry data with transformers. <i>Computers in Biology and Medicine</i> , 2022, 144, 105314.	7.0	6
5	An R307H substitution in GATA1 that prevents Ser310 phosphorylation causes severe fetal anemia. <i>Blood Advances</i> , 2022, 6, 4330-4334.	5.2	4
6	Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports). <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210994.	2.5	1
7	Features and outcome of chronic myeloid leukemia at very young age: Data from the International Pediatric Chronic Myeloid Leukemia Registry. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28706.	1.5	6
8	Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group. <i>Cancers</i> , 2021, 13, 789.	3.7	10
9	Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. <i>Cancers</i> , 2021, 13, 2336.	3.7	30
10	Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. <i>American Journal of Hematology</i> , 2021, 96, 719-726.	4.1	1
11	Diagnosis and management of acute appendicitis in 21 pediatric hematology and oncology patients at a tertiary care cancer center. <i>Scientific Reports</i> , 2021, 11, 12170.	3.3	1
12	Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2021, 56, 2732-2741.	2.4	24
13	Recommendations for Diagnosis and Treatment of Children with Transient Abnormal Myelopoiesis (TAM) and Myeloid Leukemia in Down Syndrome (ML-DS). <i>Klinische Padiatrie</i> , 2021, 233, 267-277.	0.6	4
14	The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study. <i>Leukemia Research</i> , 2021, 108, 106652.	0.8	2
15	Association of unbalanced translocation der(1;7) with germline GATA2 mutations. <i>Blood</i> , 2021, 138, 2441-2445.	1.4	12
16	Pediatric oncology 2.0 – shaping the future with precision. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 218-219.	0.5	0
17	Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. <i>Nature Medicine</i> , 2021, 27, 1806-1817.	30.7	79
18	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. <i>Blood Cancer Journal</i> , 2021, 11, 167.	6.2	11

#	ARTICLE	IF	CITATIONS
19	An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report. <i>Cancers</i> , 2021, 13, 6148.	3.7	24
20	The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. <i>Blood Advances</i> , 2020, 4, 4052-4064.	5.2	5
21	Expression Patterns of Coagulation Factor XIII Subunit A on Leukemic Lymphoblasts Correlate with Clinical Outcome and Genetic Subtypes in Childhood B-cell Progenitor Acute Lymphoblastic Leukemia. <i>Cancers</i> , 2020, 12, 2264.	3.7	2
22	Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency. <i>Leukemia</i> , 2020, 34, 2673-2687.	7.2	38
23	Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology. <i>Cancers</i> , 2020, 12, 611.	3.7	23
24	Phospho-Profiling Linking Biology and Clinics in Pediatric Acute Myeloid Leukemia. <i>HemaSphere</i> , 2020, 4, e312.	2.7	7
25	Management of children and adolescents with gray zone lymphoma: A case series. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28206.	1.5	7
26	Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG. <i>Blood</i> , 2020, 136, 26-27.	1.4	1
27	Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome. <i>Blood</i> , 2020, 136, 6-7.	1.4	1
28	Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group. <i>Blood</i> , 2020, 136, 24-24.	1.4	0
29	Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group. <i>Haematologica</i> , 2019, 104, 120-127.	3.5	38
30	Automated Flow Cytometric MRD Assessment in Childhood Acute B-Cell Lymphoblastic Leukemia Using Supervised Machine Learning. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 966-975.	1.5	40
31	Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27900.	1.5	6
32	Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies. <i>Frontiers in Pediatrics</i> , 2019, 7, 412.	1.9	27
33	CD371 cell surface expression: a unique feature of <i>DUX4</i> -rearranged acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, e352-e355.	3.5	42
34	<i>Rothia mucilaginosa</i> bacteremia: A 10-year experience of a pediatric tertiary care cancer center. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27691.	1.5	10
35	Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27590.	1.5	18
36	Impact of a Risk-Adapted Treatment Approach in Pediatric AML: A Report of the AML-BFM Registry 2012. <i>Blood</i> , 2019, 134, 293-293.	1.4	6

#	ARTICLE	IF	CITATIONS
37	Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. <i>Leukemia</i> , 2018, 32, 2167-2177.	7.2	155
38	International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. <i>Blood</i> , 2018, 132, 264-276.	1.4	70
39	In need of special care: adolescent and young adult patients with cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 5-6.	0.5	1
40	Recurrently affected genes in juvenile myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 182, 135-138.	2.5	5
41	<sc>AIEOP</sc>â€<sc>BFM</sc> Consensus Guidelines 2016 for Flow Cytometric Immunophenotyping of Pediatric Acute Lymphoblastic Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 82-93.	1.5	96
42	Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 47-53.	0.5	3
43	WGAN Latent Space Embeddings for Blast Identification in Childhood Acute Myeloid Leukaemia. , 2018, , .		4
44	Outcome of two patients with bilateral nephroblastomatosis/Wilms tumour treated with an add-on 13-cis retinoic acid therapy â€“ Case report. <i>Pediatric Hematology and Oncology</i> , 2018, 35, 218-224.	0.8	11
45	Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. <i>Blood</i> , 2018, 132, 1584-1592.	1.4	45
46	Targeted mutation screening of 292 candidate genes in 38 children with inborn haematological cytopenias efficiently identifies novel diseaseâ€causing mutations. <i>British Journal of Haematology</i> , 2018, 182, 251-258.	2.5	12
47	Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. <i>Haematologica</i> , 2018, 103, 1484-1492.	3.5	24
48	First experience of the AMLâ€Berlinâ€Frankfurtâ€MÃ¼nster group in pediatric patients with standardâ€risk acute promyelocytic leukemia treated with arsenic trioxide and allâ€i>trans</i> retinoid acid. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26461.	1.5	32
49	Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. <i>Blood</i> , 2017, 129, 3314-3321.	1.4	64
50	Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the <sc>I</sc>nternational <sc>R</sc>egistry for <sc>C</sc>hronic <sc>M</sc>yeloid <sc>L</sc>eukemia in <sc>C</sc>hildren and <sc>A</sc>dolescents. <i>Cancer</i> , 2017, 123, 3609-3616.	4.1	25
51	<i>MEF2C</i>-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with<i>CDKN1B</i>deletions and a poor response to glucocorticoid therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2895-2904.	1.3	19
52	Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26664.	1.5	14
53	Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. <i>Haematologica</i> , 2017, 102, 1704-1708.	3.5	40
54	Chronic stress induces CD99, suppresses autophagy, and affects spontaneous adipogenesis in human bone marrow stromal cells. <i>Stem Cell Research and Therapy</i> , 2017, 8, 83.	5.5	6

#	ARTICLE	IF	CITATIONS
55	High hyperdiploid acute lymphoblastic leukemia (ALL)â€”A 25â€”year populationâ€”based survey of the Austrian ALLâ€”BFM (Berlinâ€”Frankfurtâ€”MÃ¼nster) Study Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26327.	1.5	11
56	Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2017, 96, 99-106.	1.8	18
57	RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. <i>Nature Communications</i> , 2017, 8, 2126.	12.8	91
58	A Clinical Tool for Automated Flow Cytometry Based on Machine Learning Methods. <i>Lecture Notes in Computer Science</i> , 2017, , 537-548.	1.3	1
59	Exchange Transfusion and Leukapheresis in Pediatric Patients with AML With High Risk of Early Death by Bleeding and Leukostasis. <i>Pediatric Blood and Cancer</i> , 2016, 63, 640-645.	1.5	28
60	Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2016, 30, 849-862.	16.8	215
61	Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. <i>Blood</i> , 2016, 127, 1387-1397.	1.4	304
62	Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. <i>Cancer</i> , 2016, 122, 3821-3830.	4.1	92
63	Clustering of cell populations in flow cytometry data using a combination of Gaussian mixtures. <i>Pattern Recognition</i> , 2016, 60, 1029-1040.	8.1	15
64	Impact of Somatic Mutations on the Outcome of Children and Adolescents with Therapy-Related Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 3162-3162.	1.4	3
65	Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. <i>Blood</i> , 2015, 125, 2311-2313.	1.4	60
66	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. <i>Blood</i> , 2015, 126, 1575-1584.	1.4	69
67	Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, e229-e232.	3.5	29
68	Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2015, 100, 17-22.	3.5	43
69	Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM O4 trial. <i>Annals of Hematology</i> , 2015, 94, 1327-1336.	1.8	54
70	Clinical Impact of Additional Cytogenetic Aberrations, <i>ckIT</i> and <i>RAS</i> Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-MÃ¼nster Study Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 4247-4258.	1.6	75
71	Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 935-944.	3.5	64
72	Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood. <i>Haematologica</i> , 2015, 100, 315-323.	3.5	38

#	ARTICLE	IF	CITATIONS
73	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 2949-2962.	1.6	277
74	Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol. <i>Blood</i> , 2015, 126, 1414-1414.	1.4	1
75	Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 1662-1662.	1.4	9
76	Acute Leukemias of Ambiguous Lineage; Study on 247 Pediatric Patients. <i>Blood</i> , 2015, 126, 252-252.	1.4	4
77	Direct and Indirect Targets of the E2A-PBX1 Leukemia-Specific Fusion Protein. <i>PLoS ONE</i> , 2014, 9, e87602.	2.5	34
78	The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01. <i>Haematologica</i> , 2014, 99, 1472-1478.	3.5	42
79	<i>RASA4</i> undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia. <i>Epigenetics</i> , 2014, 9, 1252-1260.	2.7	34
80	CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage. <i>Leukemia</i> , 2014, 28, 609-620.	7.2	43
81	Development of treatment and clinical results in childhood AML in Austria (1993-2013). <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 63-74.	0.5	4
82	Flow diagnostics essential code: A simple and brief format for the summary of leukemia phenotyping. , 2014, 86, 288-291.		10
83	Cure and care for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries: part II. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 3-5.	0.5	2
84	Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood. <i>Haematologica</i> , 2014, 99, 656-663.	3.5	36
85	Molecular characterization and clinical impact of t(11;15)(q23;q14-15) MLL-CASC5 rearrangement. <i>Haematologica</i> , 2014, 99, e11-e13.	3.5	8
86	A Novel Fusion Gene <i>NDEL1-Pdgfrb</i> in a Patient with JMML with a New Variant of TKI-Resistant Mutation in the Kinase Domain of <i>PDGFRI2</i> . <i>Blood</i> , 2014, 124, 613-613.	1.4	5
87	Clofarabine in Combination with High-Dose Cytarabine and Liposomal Daunorubicin in Pediatric AML: Results of a Phase 1B Combination Study By the ITCC Consortium. <i>Blood</i> , 2014, 124, 989-989.	1.4	1
88	Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML. <i>Blood</i> , 2014, 124, 481-481.	1.4	0
89	Pediatric Acute Megakaryoblastic Leukemia without Down Syndrome: A Retrospective Study by the International Berlin-Frankfurt-Munster Study Group (I-BFMSC). <i>Blood</i> , 2014, 124, 3670-3670.	1.4	0
90	Bone Marrow Immunophenotyping By Flow Cytometry in Refractory Cytopenia of Childhood. <i>Blood</i> , 2014, 124, 1916-1916.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. <i>Blood</i> , 2013, 122, 37-43.	1.4	151
92	The MLL recombinome of acute leukemias in 2013. <i>Leukemia</i> , 2013, 27, 2165-2176.	7.2	393
93	Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium. <i>Journal of Clinical Oncology</i> , 2013, 31, 2460-2468.	1.6	75
94	All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene. <i>Leukemia</i> , 2013, 27, 1606-1610.	7.2	37
95	Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 599-607.	1.6	197
96	The inferior prognosis of adolescents with acute lymphoblastic leukaemia (<sc>ALL</sc>) is caused by a higher rate of treatment-related mortality and not an increased relapse rate â€“ a population-based analysis of 25 years of the <sc>A</sc>ustrian <sc>ALLâ€“BFM</sc> (Berlinâ€“Frankfurtâ€“MÃ¼nster) Study Group. <i>British Journal of Haematology</i> , 2013, 161, 556-565.	2.5	22
97	Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84, 370-378.	1.5	20
98	Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-MÃ¼nster AML-study group. <i>Blood</i> , 2013, 122, 2704-2713.	1.4	86
99	Outcome of Children and Adolescents With a Second or Third Relapse of Acute Lymphoblastic Leukemia (ALL). <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, e200-e204.	0.6	37
100	Safety and Pharmacokinetics Of Clofarabine In Combination With High-Dose Cytarabine and Liposomal Daunorubicin In Pediatric AML: Results Of a Phase 1 Combination Study By The ITCC Consortium. <i>Blood</i> , 2013, 122, 2693-2693.	1.4	1
101	Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. <i>Haematologica</i> , 2012, 97, 1582-1593.	3.5	95
102	Prevalence and Clinical Course of Viral Upper Respiratory Tract Infections in Immunocompromised Pediatric Patients With Malignancies or After Hematopoietic Stem Cell Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, 442-449.	0.6	17
103	Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. <i>Blood</i> , 2012, 119, e96-e99.	1.4	65
104	Thiamine-responsive megaloblastic anemia (TRMA) in an Austrian boy with compound heterozygous SLC19A2 mutations. <i>European Journal of Pediatrics</i> , 2012, 171, 1711-1715.	2.7	24
105	The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. <i>Haematologica</i> , 2012, 97, 21-29.	3.5	78
106	Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. <i>Blood</i> , 2012, 120, 3187-3205.	1.4	451
107	Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. <i>Leukemia</i> , 2012, 26, 654-661.	7.2	60
108	Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during Berlinâ€“Frankfurtâ€“MÃ¼nster-based induction therapy for childhood acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1682-1687.	1.3	12

#	ARTICLE	IF	CITATIONS
109	Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts. <i>Leukemia</i> , 2012, 26, 927-933.	7.2	50
110	Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 25-34.	1.5	39
111	Unexpected High Frequency of GATA2 Mutations in Children with Non-Familial MDS and Monosomy 7. <i>Blood</i> , 2012, 120, 1699-1699.	1.4	7
112	High Frequency of GATA1 Mutations in Childhood Non-Down Syndrome Acute Megakaryoblastic Leukemia. <i>Blood</i> , 2012, 120, 888-888.	1.4	3
113	JMML Revisited: Role and Outcome of Hematopoietic Stem Cell Transplantation in Subtypes of Juvenile Myelomonocytic Leukemia (JMML). <i>Blood</i> , 2012, 120, 955-955.	1.4	4
114	Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Münster AML Study Group. <i>Blood</i> , 2012, 120, 2516-2516.	1.4	0
115	Abnormal promoter DNA methylation in juvenile myelomonocytic leukemia is not caused by mutation in DNMT3A. <i>Blood</i> , 2011, 118, 4490-4491.	1.4	7
116	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. <i>Blood</i> , 2011, 117, 7102-7111.	1.4	58
117	Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. <i>Blood</i> , 2011, 118, 2077-2084.	1.4	370
118	Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). <i>Blood</i> , 2011, 118, 5409-5415.	1.4	56
119	High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. <i>Blood</i> , 2011, 117, 3409-3420.	1.4	168
120	CNS irradiation in pediatric acute myeloid leukemia: Equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. <i>Pediatric Blood and Cancer</i> , 2011, 57, 986-992.	1.5	25
121	Cytochemically Myeloperoxidase Positive Childhood Acute Leukemia With Lymphoblastic Morphology Treated as Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, e4-e7.	0.6	9
122	CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 3763-3771.	1.4	26
123	Diagnosis of invasive fungal infections by a real-time panfungal PCR assay in immunocompromised pediatric patients. <i>Leukemia</i> , 2010, 24, 2032-2038.	7.2	67
124	Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD Study Group. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, 147-153.	1.5	46
125	Prognostic relevance of <i>TLX3</i> (<i>HOX11L2</i>) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements. <i>British Journal of Haematology</i> , 2010, 148, 293-300.	2.5	19
126	Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. <i>British Journal of Haematology</i> , 2010, 148, 768-776.	2.5	75

#	ARTICLE	IF	CITATIONS
127	Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. <i>British Journal of Haematology</i> , 2010, 149, 84-92.	2.5	92
128	Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy. <i>British Journal of Haematology</i> , 2010, 149, 93-100.	2.5	18
129	Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. <i>British Journal of Haematology</i> , 2010, 149, 399-409.	2.5	52
130	Acute monocytic leukaemia originating from <i>MLL-MLL3</i> -positive pre-B cells. <i>British Journal of Haematology</i> , 2010, 150, 621-623.	2.5	10
131	Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. <i>Leukemia</i> , 2010, 24, 521-535.	7.2	302
132	Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. <i>Leukemia</i> , 2010, 24, 1422-1428.	7.2	124
133	Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98. <i>Journal of Clinical Oncology</i> , 2010, 28, 2682-2689.	1.6	190
134	Death induction by CD99 ligation in TEL/AML1-positive acute lymphoblastic leukemia and normal B cell precursors. <i>Journal of Leukocyte Biology</i> , 2010, 88, 405-412.	3.3	27
135	Granulocyte Colony-Stimulating Factor (G-CSF) Treatment of Childhood Acute Myeloid Leukemias That Overexpress the Differentiation-Defective <i>G-CSF</i> Receptor Isoform IV Is Associated With a Higher Incidence of Relapse. <i>Journal of Clinical Oncology</i> , 2010, 28, 2591-2597.	1.6	62
136	Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow. <i>Journal of Clinical Oncology</i> , 2009, 27, 5168-5174.	1.6	247
137	Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria - A population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. <i>British Journal of Haematology</i> , 2009, 144, 559-570.	2.5	61
138	Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. <i>Leukemia</i> , 2009, 23, 528-534.	7.2	56
139	Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Münster study group. <i>Leukemia</i> , 2009, 23, 1264-1269.	7.2	71
140	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. <i>Blood</i> , 2009, 114, 2489-2496.	1.4	383
141	Preventive CNS Irradiation with 12 Gy Compared to 18 Gy: Results of Studies AML-BFM 98 and 2004.. <i>Blood</i> , 2009, 114, 483-483.	1.4	1
142	Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2008, 74B, 150-155.	1.5	51
143	Nodular pulmonary lesions in children after autologous stem cell transplantation: a source of misinterpretation. <i>British Journal of Haematology</i> , 2008, 140, 429-432.	2.5	7
144	Compliance with anti-infective preventive measures: A multicentre survey among paediatric oncology patients. <i>European Journal of Cancer</i> , 2008, 44, 1861-1865.	2.8	24

#	ARTICLE	IF	CITATIONS
145	Minimal Residual Disease Values Discriminate Between Low and High Relapse Risk in Children With B-Cell Precursor Acute Lymphoblastic Leukemia and an Intrachromosomal Amplification of Chromosome 21: The Austrian and German Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster (ALL-BFM) Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 3046-3050.	1.6	108
146	Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. <i>Blood</i> , 2008, 111, 2991-2998.	1.4	228
147	CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. <i>Blood</i> , 2008, 112, 3982-3988.	1.4	134
148	Time Point-Dependent Concordance of Flow Cytometry and RQ-PCR in the MRD Detection in Childhood ALL: The Experience of the AIEOP-BFM- ALL MRD Study Group. <i>Blood</i> , 2008, 112, 700-700.	1.4	3
149	Integrin Alpha M Chain Expression at Diagnosis Is Inversely Correlated with Cyto-reduction Rate and Is Consistently Up-Regulated during Therapy in Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2008, 112, 2526-2526.	1.4	0
150	Distribution and Outcome According to Cytogenetics in 502 Paediatric AML Patients Treated in Study AML-BFM 98.. <i>Blood</i> , 2008, 112, 1510-1510.	1.4	2
151	Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children. <i>Haematologica</i> , 2007, 92, 1561-1564.	3.5	55
152	Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. <i>Blood</i> , 2007, 109, 936-943.	1.4	52
153	Bone marrow assessment in Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2007, 49, 694-698.	1.5	39
154	Residual Disease Monitoring in Childhood Acute Myeloid Leukemia by Multiparameter Flow Cytometry: The MRD-AML-BFM Study Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 3686-3692.	1.6	132
155	Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98. <i>Journal of Clinical Oncology</i> , 2006, 24, 4499-4506.	1.6	173
156	Mixed Lineage Leukemia—Rearranged Childhood Pro-B and CD10-Negative Pre-B Acute Lymphoblastic Leukemia Constitute a Distinct Clinical Entity. <i>Clinical Cancer Research</i> , 2006, 12, 2988-2994.	7.0	40
157	Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 527-535.	3.0	75
158	Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: A population-based analysis of the Austrian cooperative study group. <i>Pediatric Blood and Cancer</i> , 2005, 44, 70-76.	1.5	61
159	Treatment Response and Outcome in Childhood t(1;19)/TCF3-PBX1 Positive Acute Lymphoblastic Leukemia: A Report from the Austrian BFM Group.. <i>Blood</i> , 2005, 106, 1458-1458.	1.4	1
160	Minimal Residual Disease Monitoring by Four Color Flow Cytometry before Second Induction Is an Independent Prognostic Factor in Childhood Acute Myeloid Leukemia - AML-BFM MRD Study Group.. <i>Blood</i> , 2005, 106, 671-671.	1.4	0
161	Screening for NUP98 rearrangements in hematopoietic malignancies by fluorescence in situ hybridization. <i>Haematologica</i> , 2005, 90, 746-52.	3.5	22
162	Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98. <i>Journal of Clinical Oncology</i> , 2004, 22, 4384-4393.	1.6	230

#	ARTICLE	IF	CITATIONS
163	Flow Cytometric Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 1445-1455.	1.3	25
164	Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. <i>Haematologica</i> , 2003, 88, 1245-52.	3.5	52
165	Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2002, 99, 1952-1958.	1.4	294
166	The role of surgery in the treatment of pediatric B-cell non-Hodgkin's lymphoma. <i>Journal of Pediatric Surgery</i> , 2002, 37, 1470-1475.	1.6	23
167	Mediastinal mass in childhood T-cell acute lymphoblastic leukemia: Significance and therapy response. <i>Medical and Pediatric Oncology</i> , 2002, 39, 558-565.	1.0	29
168	Treatment results of childhood acute lymphoblastic leukemia in Austria—a report of 20 years' experience. <i>Wiener Klinische Wochenschrift</i> , 2002, 114, 148-57.	1.9	6
169	CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis. <i>British Journal of Haematology</i> , 1999, 105, 690-695.	2.5	49
170	Skin-associated lymphocytes in the peripheral blood of patients with atopic dermatitis: Signs of subset expansion and stimulation. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 103, 901-906.	2.9	39
171	Structure of the human TNF receptor 1 (p60) gene (TNRF1) and localization to chromosome 12p13. <i>Genomics</i> , 1992, 13, 219-224.	2.9	76
172	Case Report: Refractory Cytopenia With a Switch From a Transient Monosomy 7 to a Disease-Ameliorating del(20q) in a NHEJ1-Deficient Long-term Survivor. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
173	Second malignant neoplasms after treatment of 1487 children and adolescents with acute lymphoblastic leukemia—A population-based analysis of the Austrian ALL-BFM Study Group. <i>EJHaem</i> , 0, , .	1.0	0
174	Incidence and Risk Factors of Venous Thromboembolism in Childhood Acute Lymphoblastic Leukaemia — a Population-Based Analysis of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. <i>Pediatric Hematology and Oncology</i> , 0, , 1-11.	0.8	0